Skip to content Skip to navigation

Medication

Brightside Clinic hires medical director

March 20, 2017  |  Gary A. Enos, Editor
news
David Kushner, DO, FACP, has been named medical director at Brightside Clinic, the buprenorphine treatment organization with offices in two Illinois communities.

Report: Risk of long-term opioid use increases in initial week of treatment

March 17, 2017  |  Gary A. Enos, Editor
article
Data released this week by the Centers for Disease Control and Prevention (CDC) make a case for significant limits on initial prescriptions of opioids.

Study highlights threat of dual use of buprenorphine and other opioids

March 7, 2017  |  Rachael Zimlich, RN, Contributing Writer
article
Research using a pharmacy database leads to striking findings about the prevalence of other opioid use during and after buprenorphine treatment.

Academic event stresses teamwork in treating opioid addiction

February 17, 2017  |  Gary A. Enos, Editor
article
A Maine university seeks to prepare students in a variety of health disciplines to work together in combating the effects of the opioid crisis.

Researchers quantify benefit of medication intervention in emergency care

February 14, 2017  |  Gary A. Enos, Editor
news
New research suggests that opioid-addicted individuals who receive buprenorphine during an emergency medical visit show better treatment engagement for two months following the intervention.

Counselors shed an either-or mindset

February 1, 2017  |  Gary A. Enos, Editor
article
Responses to Addiction Professional's Quality of Life Survey show support for both 12-Step approaches and medication treatments.

Five facts about new versions of buprenorphine

January 13, 2017  |  Gary A. Enos, Editor
article
Injectable and implant versions of buprenorphine are seen as potentially significant breakthroughs in improving medication adherence and reducing diversion.

FDA will remove warning language on drugs for smoking cessation

December 19, 2016  |  Gary A. Enos, Editor
news
Results of a clinical trial have convinced the Food and Drug Administration (FDA) that the risk of neuropsychiatric adverse events from the brand-name drugs Chantix and Zyban is lower than originally believed.

Settlement over prescribing practices puts spotlight on buprenorphine clinics

December 2, 2016  |  Gary A. Enos, Editor
article
A well-regarded chain of buprenorphine treatment operations has agreed to pay a civil settlement in a case that in part speaks to concerns about the mix of services in medication-assisted treatment facilities.

App from SAMHSA guides medication treatment for opioid dependence

December 1, 2016  |  Gary A. Enos, Editor
news
The new MATx app is designed to share treatment strategies and other resources for the use of medications to treat opioid use disorders.

Transformed thinking gives rise to center of excellence in addiction medicine

November 23, 2016  |  Gary A. Enos, Editor
article
In establishing unified addiction services that earned a first-ever recognition this month, the Center for Addiction Science in Tennessee showed how patients can flourish when they receive care in a humane manner.

Midlevel practitioners will soon prescribe buprenorphine

November 22, 2016  |  Julie Miller, Editor in Chief
article
A new 2017 federal policy will allow physician assistants and nurse practitioners to prescribe buprenorphine. Previously, only physicians were authorized to prescribe the medication.

Pages

Subscribe to Medication